regulated in the upper gastrointestinal carcinoma. Up to date, the role of COBRA1 in hepatocellular carcinoma (HCC) is unclear. We have previously demonstrated that silencing of COBRA1
vitro anti-TB and cytotoxicity index, using Human Embryonic Kidney (HEK 293) and Human Hepatocellular carcinoma (HepG2) cells. The PXRD of the synthesized co-crystal compound maintained crystalline nature like
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is a leading cause of cancer- related death worldwide. In the United States, HCC is the ninth leading cause
Egypt with prevalence of (HCV) which represent from 5 to 7% of total population. Hepatocellular carcinoma is one of major complications of HCV infection At Africa for example Egypt ... this study was to conduct an…
aimed to investigate the role of angiotensin II and NF-kB pathway in liver hepatocellular carcinoma cell line (HepG2) proliferation by using azilsartan (as a novel Ag II antagonist
currently used clinical and pathologic prognostic parameters are not fully valid in all hepatocellular carcinoma (HCC) cases, since HCC is highly heterogeneous and tumors with similar clinical and pathological features
Thailand, hepatocellular carcinoma (HCC) ranks as number one cancer in men and fourth in women. It is also the major cause of death in men and ranks second in women
well-known that over activation of NF-кB has close relationship with hepatitis and hepatocellular carcinoma (HCC). However, the complete and exact underlying molecular pathways and mechanisms still remain
drugs; (captopril, rosuvastatin and omega 3) in combination with DOX against diethylnitrosamine (DEN)-induced hepatocellular (HCC) in mice, in an attempt to achieve an improved antitumoral effect devoid of cardiotoxicity
mortality was comparable between the groups (SMR: 1.10, 95% CI: 0.93-1.32). Among malignancies, hepatocellular carcinoma (HCC) conferred the highest mortality risk in T2D patients
tested compounds 4, 5, 8, 12, 13 and 14 were non-cytotoxic against hepatocellular carcinoma cells (HepG2) using MMT. These non-cytotoxic compounds were evaluated as anti-angiogenicagent. Collectively
Background: An increasingly high occurrence of bone metastases in hepatocellular carcinoma (HCC) patients highlights the importance of fundamental research on HCC bone metastasis, which has been limited in its success
microRNA-141 and 215 to differentiate between liver cirrhosis, chronic hepatitis C (CHC) and hepatocellular carcinoma (HCC) patients. Patients & Methods: The study included 25 liver cirrhosis patients, 25 CHC patients
occurrence of hepatocellular carcinoma is rising especially in areas with high incidence of viral hepatitis. Fine needle aspiration is a safe, cost effective and accurate method for diagnosis of liver ... cytology of…
Hepatocellular carcinoma (HCC) occurs at the rate of more than 500,000 cases and is the 6th most common cause of cancer worldwide. It is also the 3rd leading cause ... cancer related death. Currently, increasing number…
only FDA approved agent that has been shown to prolong survival in unresectable hepatocellular carcinoma (HCC). The recommended dose is 400mg BID. Our anecdotal experience has shown that the majority
salivary pH to reflect the state of chronic metabolic acidosis in patients with hepatocellular carcinoma. Salivary pH was measured in 300 subjects using narrow range pH strips. Subjects were divided
formation of hepatocellular carcinoma (HCC) is a chronic progress including hepatitis, steatosis, fibrosis, cirrhosis. Liver cancer is the third most common cancer worldwide and ranked as a leading cause
Background: Serum alpha-fetoprotein (AFP) has insufficient sensitivity and specificity for detection of hepatocellular carcinoma (HCC). Recently, glypican-3 (GLP-3) was suggested as a new biomarker for the detection
investigate whether the long-term outcomes of Hepatocellular carcinoma (HCC) was adversely impacted by intermittent hepatic inflow occlusion (HIO) during hepatic resection. Study design: We performed a cohort study
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.